Compare InMode Ltd (INMD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? InMode Ltd trades at $15.31 (market cap $882.90M), while State Street SPDR S&P Biotech ETF trades at $153.62. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.
| INMD | XBI | |
|---|---|---|
Market Cap | $882.90M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $16.62 | $164.28 |
52-Week Low | $12.76 | $85.16 |
Enterprise Value | $350.57M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.36, down 0.71% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and upcoming Q2 2026 results on August 5, 2026.
The stock presents a mixed outlook: attractive valuation multiples and a solid balance sheet support upside, but risks include earnings volatility, shareholder activism, and a securities fraud investigation. Analyst consensus is a $16.50 price target with a balanced buy/hold rating split, suggesting cautious optimism near-term.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
